CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1100682 · Fiscal year ends 12/27
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.2%
TTM net income YoY148.8%
TTM EPS YoY160.5%
Revenue 3-yr CAGR-1.9%
Net income 3-yr CAGR-56.1%
Margins
Gross margin—
Operating margin4.0%
Net margin1.0%
FCF margin10.0%
EBITDA margin11.2%
Returns
ROE1.2%
ROA0.5%
ROIC (approx.)2.3%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets56.0%
Debt / equity0.76x
Current ratio1.41x
Interest coverage1.45x
Cash quality & payout
Operating cash flow / net income15.49x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-27 | FY20242024-12-28 | FY20232023-12-30 | FY20222022-12-31 | FY20212021-12-25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| SG&A expense | $743.07M | $751.00M | $747.86M | $665.10M | $619.92M |
| Operating income | $25.16M | $227.35M | $617.26M | $650.98M | $589.86M |
| Interest expense | $107.03M | $126.29M | $136.71M | $59.29M | $73.91M |
| Pretax income | -$99.50M | $93.11M | $581.28M | $622.99M | $480.71M |
| Income tax | $42.66M | $67.82M | $100.91M | $130.38M | $81.87M |
| Net income | -$144.34M | $22.20M | $474.62M | $486.23M | $390.98M |
| EBITDA | $428.47M | $589.09M | $931.38M | $954.85M | $855.40M |
| EPS (basic) | -2.91 | 0.20 | 9.27 | 9.57 | 7.77 |
| EPS (diluted) | -2.91 | 0.20 | 9.22 | 9.48 | 7.60 |
| Weighted avg. shares (diluted) | 49.56M | 51.63M | 51.45M | 51.30M | 51.42M |
| Banking | |||||
| Provision for credit losses | — | — | — | $6.71M | $1.66M |
| Balance sheet | |||||
| Cash & equivalents | $213.77M | $205.57M | $284.48M | $241.21M | $246.31M |
| Short-term investments | — | — | — | — | $1.06M |
| Receivables | $708.86M | $720.91M | $780.38M | $752.39M | $642.88M |
| Inventory | $299.10M | $278.54M | $380.26M | $255.81M | $199.15M |
| Current assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B |
| PP&E, net | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B |
| Intangibles | $340.00M | $723.40M | $864.05M | $955.27M | $1.06B |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B |
| Current liabilities | $1.12B | $994.10M | $1.06B | $1.09B | $1.03B |
| Short-term debt | $166,000 | $155,000 | $3.17M | $1.35M | $101,000 |
| Long-term debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B |
| Total debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B |
| Shareholders' equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B |
| Net debt | $1.92B | $2.03B | $2.37B | $2.47B | $2.42B |
| Shares outstanding | 49.22M | 51.14M | 51.34M | 50.94M | 50.48M |
| Cash flow statement | |||||
| Operating cash flow | $737.65M | $734.58M | $683.90M | $619.64M | $760.80M |
| Capital expenditure | $219.15M | $232.97M | $318.53M | $324.73M | $228.77M |
| Free cash flow | $518.49M | $501.61M | $365.37M | $294.91M | $532.03M |
| Investing cash flow | -$209.32M | -$245.09M | -$563.15M | -$607.92M | -$1.44B |
| Financing cash flow | -$536.73M | -$550.93M | -$85.52M | -$42.40M | $672.60M |
| Depreciation & amortization | $403.31M | $361.74M | $314.12M | $303.87M | $265.54M |
| Stock-based compensation | $71.08M | $69.89M | $72.05M | $73.62M | $71.47M |
| Share buybacks | $360.67M | $119.17M | $24.16M | $38.65M | $40.71M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.